TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Algert Global LLC

Algert Global LLC lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 52.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,061 shares of the biopharmaceutical company’s stock after selling 55,191 shares during the quarter. Algert Global LLC’s holdings in TG Therapeutics were worth $1,477,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of TGTX. Quadrant Capital Group LLC lifted its holdings in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 975 shares during the last quarter. Blue Trust Inc. boosted its holdings in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC bought a new position in shares of TG Therapeutics in the 4th quarter worth about $75,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on TGTX. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.80.

TG Therapeutics Stock Performance

TGTX opened at $33.64 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The business’s 50 day moving average is $38.90 and its 200-day moving average is $33.56. The stock has a market cap of $5.34 billion, a PE ratio of -336.37 and a beta of 2.21. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue was up 90.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.07) EPS. On average, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.